<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468673</url>
  </required_header>
  <id_info>
    <org_study_id>PROunit PROQOL-SexLife ANRS</org_study_id>
    <nct_id>NCT03468673</nct_id>
  </id_info>
  <brief_title>International Validation of a Sexual Quality of Life Questionnaire Specific to HIV and Hepatitis C (PROQOL-SexLife)</brief_title>
  <acronym>SexLife</acronym>
  <official_title>International Validation of a Sexual Quality of Life Questionnaire Specific to HIV and Hepatitis C Infections (PROQOL-SexLife)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Paris 7 - Denis Diderot</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center of treatment HIV/Aids-São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Paris 7 - Denis Diderot</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop and validate a specific questionnaire of sexual quality of life in several&#xD;
      languages and cultures (France, Brazil, Australia) allowing a meaningful and comprehensive&#xD;
      assessment of the sexuality of patients infected with HIV and HCV; Propose reference scoring&#xD;
      for sub-populations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sexual health is a complex construct affecting physical, mental and social well-being.&#xD;
      According to studies, sexual disorders are common in people with HIV infection and 25 to 71%&#xD;
      of, both men and women regardless of their sexual orientation; and between 39 and 50 % of&#xD;
      patients infected with Hepatitis C Virus(HCV). The cause is almost always multifactorial,&#xD;
      with psychological, environmental and physiological components, and there may be an&#xD;
      iatrogenic effect of treatment. HIV is a chronic disease for people with access to effective&#xD;
      treatment. And Hepatitis C while curable is a chronic condition when untreated. In this&#xD;
      context, sexuality is an important dimension of quality of life. But the issues are complex&#xD;
      and not easily defined. Various studies have highlighted the lack of attention paid to&#xD;
      sexuality in a medical management of various chronic conditions such as HIV or cancer.&#xD;
      Indeed, a preliminary review of the literature and analysis of the concepts measured by 25&#xD;
      questionnaires on sexuality, shows that these instruments are inadequate to capture all&#xD;
      aspects of the sexuality affecting quality of life of people infected with HIV or HCV. If&#xD;
      they address physical aspects of sexuality, they address briefly at all socio-psychological&#xD;
      and relational sexual life (body image, feeling desirable, self-esteem). Only a limited&#xD;
      number of studies focused specifically on the experience of people suffering of sexual&#xD;
      dysfunction in HIV and HCV infection. Moreover, these instruments do not assess specific&#xD;
      issues related to stigma and problems related to transmission of infections of certain&#xD;
      subgroups, particularly in the gay population.&#xD;
&#xD;
      It is an international prospective study (Australia, Brazil, Canada and France) with four&#xD;
      phases:&#xD;
&#xD;
      Phase 1. A literature review and interview guide writing.&#xD;
&#xD;
      Phase 2. A qualitative research design based on a grounded theory research perspective:&#xD;
&#xD;
      realization and analysis of interviews with people affected by HIV and HCV, creation of the&#xD;
      conceptual framework specific to HIV and HCV.&#xD;
&#xD;
      Phase 3. Questionnaire creation: creation of an item bank; formalization of a pilot&#xD;
      questionnaire; forward-backward linguistic validation in each of the target languages&#xD;
      (French, Portuguese of Brazil, English), cognitive debriefing and international&#xD;
      harmonization; development of the conceptual model of sexual quality of life.&#xD;
&#xD;
      Phase 4. Psychometric validation of the new questionnaire: cross-sectional study by&#xD;
      administration of the new questionnaire to 1 400 patients in the 4 countries, along with&#xD;
      generic questionnaire about sexuality (Male sexual Health Questionnaire, Female sexual&#xD;
      Function Index), the HIV sexual risk questionnaire, and the SF-12v2; Statistic and&#xD;
      psychometric analysis; assessment of characteristics of different sub-populations; Propose&#xD;
      reference scoring for sub- populations.&#xD;
&#xD;
      Impact of research: the availability of a meaningful and validated tool to detect and assess&#xD;
      specifically sexual quality of life in HIV and HCV populations will improve the understanding&#xD;
      of specific issues of these sub-populations. The questionnaire is intended for use in&#xD;
      research, clinical practice, and during annual visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2015</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometric validation of a new questionnaire (PROQOL-SexLife) to assess sexual Quality of Life of people affected by HIV and HCV</measure>
    <time_frame>4 last weeks</time_frame>
    <description>PROQOL-SexLife is the developed questionnaire through qualitative analysis (phase 2 of the study). Because it is specific to these infections, it will be used to assess the sexuality of people affected by HIV and / or Hepatitis C. This questionnaire has the potential to specifically detect sexual dysfunction. It is intended for use in research, clinical practice, and during annual visits.</description>
  </primary_outcome>
  <enrollment type="Actual">1164</enrollment>
  <condition>Sexual Dysfunction</condition>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <eligibility>
    <study_pop>
      <textblock>
        People living with HIV and / or HCV and being over the age of 18, and having proficiency in&#xD;
        English, French or Portuguese&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  People living with HIV and/or Hepatitis C&#xD;
&#xD;
          -  having proficiency in English, French or Portuguese of Brazil&#xD;
&#xD;
          -  Giving informed consent (oral or written consent according to the legislation of&#xD;
             country)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cognitive impairment or major psychiatric disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Sydney</name>
      <address>
        <city>Sydney</city>
        <zip>2006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of treatment HIV/Aids - Brazil</name>
      <address>
        <city>são Paulo</city>
        <zip>04121-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique m&amp;dicale L'Actuel</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hôtel-Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutual Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Saint Germain en Laye</name>
      <address>
        <city>Saint Germain en Laye</city>
        <zip>78100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Saint-Nazaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059 cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hépato -Biliaire de l'Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>WHO | Sexual health [Internet]. WHO. Available from: http://www.who.int/topics/sexual_health/en/</citation>
  </reference>
  <reference>
    <citation>Koole O, Noestlinger C, Colebunders R. Quality of life in HIV clinical trials: why sexual health must not be ignored. PLoS Clin Trials. 2007 Mar 2;2(3):e8.</citation>
    <PMID>17332849</PMID>
  </reference>
  <reference>
    <citation>Marcellin F, Préau M, Ravaux I, Dellamonica P, Spire B, Carrieri MP. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin Trials. 2007 Sep-Oct;8(5):320-7.</citation>
    <PMID>17956833</PMID>
  </reference>
  <reference>
    <citation>Sandfort TG, Collier KL, Grossberg R. Addressing sexual problems in HIV primary care: experiences from patients. Arch Sex Behav. 2013 Oct;42(7):1357-68. doi: 10.1007/s10508-012-0009-5. Epub 2012 Sep 11.</citation>
    <PMID>22965768</PMID>
  </reference>
  <reference>
    <citation>Meystre-Agustoni G, Jeannin A, de Heller K, Pécoud A, Bodenmann P, Dubois-Arber F. Talking about sexuality with the physician: are patients receiving what they wish? Swiss Med Wkly. 2011 Mar 8;141:w13178. doi: 10.4414/smw.2011.13178. eCollection 2011.</citation>
    <PMID>21384286</PMID>
  </reference>
  <reference>
    <citation>Dyer K, das Nair R. Why don't healthcare professionals talk about sex? A systematic review of recent qualitative studies conducted in the United kingdom. J Sex Med. 2013 Nov;10(11):2658-70. doi: 10.1111/j.1743-6109.2012.02856.x. Epub 2012 Jul 30. Review.</citation>
    <PMID>22846467</PMID>
  </reference>
  <reference>
    <citation>Soykan A, Boztaş H, Idilman R, Ozel ET, Tüzün AE, Ozden A, Ozden A, Kumbasar H. Sexual dysfunctions in HCV patients and its correlations with psychological and biological variables. Int J Impot Res. 2005 Mar-Apr;17(2):175-9.</citation>
    <PMID>15510190</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Paris 7 - Denis Diderot</investigator_affiliation>
    <investigator_full_name>Dr Martin Duracinsky</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>AIDS</keyword>
  <keyword>HCV</keyword>
  <keyword>Questionnaire</keyword>
  <keyword>Qualitative analysis</keyword>
  <keyword>Sexual Quality of Life</keyword>
  <keyword>Psychometric validation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

